S Stein, A Bachmann, U Lössner, J Kratzsch, … - Diabetes Care, 2009 - Am Diabetes Assoc OBJECTIVE—To investigate renal elimination of the adipokine fibroblast growth
factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic
hemodialysis (CD) as compared with control subjects with a glomerular ... Cited by 1 - Related articles - All 3 versions
R Micanovic, DW Raches, JD Dunbar, DA … - J Cell Physiol, 2009 - interscience.wiley.com Fibroblast growth factor 21 is a member of endocrine FGFs subfamily, along with
FGF19 and FGF23. It is emerging as a novel regulator with beneficial effects on
a variety of metabolic parameters, including glucose and lipid control. ... Cited by 5 - Related articles - All 2 versions
- ►pubget.com [PDF] J Yie, R Hecht, J Patel, J Stevens, W Wang, N … - FEBS letters, 2009 - Elsevier Fibroblast growth factor-21 (FGF21) signaling requires the presence of
β-Klotho, a co-receptor with a very short cytoplasmic domain. Here we show that
FGF21 binds directly to β-Klotho through its C-terminus. Serial C-terminal ... Cited by 5 - Related articles - All 3 versions
- ►physiology.org EJ Stevenson, A Koncarevic, PG Giresi, RW … - Journal of Applied Physiology, 2005 - Am Physiological Soc Skeletal muscle wasting is a pervasive phenomenon that can result from a wide
range of pathological conditions as well as from habitual muscular inactivity.
The present work describes a cell-culture condition that induces ... Cited by 8 - Related articles - All 6 versions
- ►endojournals.org I Dostalova, P Kavalkova, D Haluzikova, Z … - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Context: Fibroblast growth factor 19 (FGF19) and FGF21 are novel metabolic
regulators that improve insulin sensitivity and decrease adiposity in mice.
However, little is known about the nutritional regulation of these factors ... Cited by 9 - Related articles - All 3 versions
- ►aspetjournals.org ES Muise, B Azzolina, DW Kuo, M El- … - Molecular Pharmacology, 2008 - ASPET Adipose tissue is a metabolically responsive endocrine organ that secretes a
myriad of adipokines. Antidiabetic drugs such as peroxisome
proliferator-activated receptor (PPAR) agonists target adipose tissue gene ... Cited by 10 - Related articles - All 3 versions
CZ Larter, MM Yeh, J Williams, KS Bell- … - Journal of Hepatology, 2008 - Elsevier MCD feeding increased serum ALT levels and induced hepatic steatosis, lobular
inflammation and ballooning degeneration of hepatocytes, irrespective of dietary
fat content. Hepatic triglyceride accumulation was similar between high and ... Cited by 10 - Related articles - All 18 versions
S O'Rahilly - Eating and weight disorders: EWD, 2001 - ncbi.nlm.nih.gov 1: Eat Weight Disord. 2001 Sep;6(3 Suppl):21. Leptin: pathophysiology and
implications for therapy. O'Rahilly S. Department of Medicine ... Cited by 2 - Related articles - BL Direct
M Rydén - Cellular and Molecular Life Sciences, 2009 - Springer Abstract Fibroblast growth factor 21 (FGF21) has been proposed as a novel
putative therapeutic agent in type 2 diabetes. A large amount of data,
predominantly obtained from murine models but also from non-human primates, ... Cited by 1 - Related articles - All 2 versions
L Li, G Yang, H Ning, M Yang, H Liu, W Chen - Diabetes Research and Clinical Practice, 2008 - Elsevier FGF-21 has been recently characterized as a potent metabolic regulator, but its
pathophysiologic role in human remains unknown. In this study we investigate
whether plasma FGF-21 level is different in patients with new-onset type 2 ... Cited by 2 - Related articles - All 13 versions
